Barclays PLC boosted its stake in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 9.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,079 shares of the company's stock after buying an additional 25,365 shares during the quarter. Barclays PLC owned approximately 0.49% of Inari Medical worth $11,881,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of NARI. Vestal Point Capital LP grew its holdings in shares of Inari Medical by 342.9% in the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock worth $71,324,000 after buying an additional 786,691 shares during the last quarter. Armistice Capital LLC increased its holdings in shares of Inari Medical by 353.1% during the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock worth $48,595,000 after buying an additional 786,501 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Inari Medical by 63.2% during the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock worth $65,021,000 after buying an additional 610,468 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Inari Medical by 101.3% in the third quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company's stock valued at $32,790,000 after acquiring an additional 400,198 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.
Shares of NARI stock opened at $55.59 on Monday. The stock has a 50-day moving average of $48.70 and a 200-day moving average of $47.95. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13. The stock has a market cap of $3.25 billion, a PE ratio of -41.18 and a beta of 0.97.
NARI has been the subject of a number of recent analyst reports. Leerink Partners began coverage on Inari Medical in a report on Tuesday, September 3rd. They set a "market perform" rating and a $47.00 price target for the company. Robert W. Baird raised their target price on Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a research note on Tuesday, October 29th. Leerink Partnrs upgraded shares of Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. Stifel Nicolaus assumed coverage on shares of Inari Medical in a report on Tuesday, September 17th. They set a "hold" rating and a $50.00 price objective on the stock. Finally, Truist Financial increased their price target on shares of Inari Medical from $46.00 to $50.00 and gave the company a "hold" rating in a research note on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $58.89.
Read Our Latest Report on NARI
In other Inari Medical news, Director William Hoffman sold 60,000 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the sale, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. This trade represents a 10.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the sale, the chief executive officer now owns 445,310 shares in the company, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 143,000 shares of company stock worth $7,022,400 in the last quarter. Corporate insiders own 10.60% of the company's stock.
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Inari Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.
While Inari Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.